Drugs / KTX-1001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05651932 | Feb 2023 → Dec 2027 expected | plasma cell myeloma | K36 Therapeutics, Inc. | Recruiting | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | KTX-1001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05651932 ↗ |
| Action | Inhibit | “small molecule inhibitor of the histone lysine methyl transferase MMSET” NCT05651932 ↗ |
| Modality | Small molecule | “a novel, orally available, selective, and potent small molecule inhibitor of the histone lysine methyl transferase MMSET” NCT05651932 ↗ |
| Route | Oral | “KTX-1001: Orally for 28 days each cycle until progression” NCT05651932 ↗ |
| Target | NSD2 | “inhibitor of the histone lysine methyl transferase MMSET (also known as NSD2/WHSC1)” NCT05651932 ↗ |